FI112367B - Menetelmiä bakterisidisen/läpäisevyyttä parantavan proteiinin tai sen biologisesti aktiivisten fragmenttien polypeptidianalogin tai sitä sisältävän hybridifuusioproteiinin valmistamiseksi sekä menetelmissä käyttökelpoisia DNA-sekvenssejä, vektoreita ja isäntäsoluja - Google Patents

Menetelmiä bakterisidisen/läpäisevyyttä parantavan proteiinin tai sen biologisesti aktiivisten fragmenttien polypeptidianalogin tai sitä sisältävän hybridifuusioproteiinin valmistamiseksi sekä menetelmissä käyttökelpoisia DNA-sekvenssejä, vektoreita ja isäntäsoluja Download PDF

Info

Publication number
FI112367B
FI112367B FI953658A FI953658A FI112367B FI 112367 B FI112367 B FI 112367B FI 953658 A FI953658 A FI 953658A FI 953658 A FI953658 A FI 953658A FI 112367 B FI112367 B FI 112367B
Authority
FI
Finland
Prior art keywords
rbpi
protein
dna
bpi
cells
Prior art date
Application number
FI953658A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI953658A0 (fi
FI953658L (fi
Inventor
Arnold Horwitz
David Burke
Georgia Theofan
Manik Baltaian
Lynn Grinna
Original Assignee
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Corp filed Critical Xoma Corp
Publication of FI953658A0 publication Critical patent/FI953658A0/fi
Publication of FI953658L publication Critical patent/FI953658L/fi
Application granted granted Critical
Publication of FI112367B publication Critical patent/FI112367B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
FI953658A 1993-02-02 1995-08-01 Menetelmiä bakterisidisen/läpäisevyyttä parantavan proteiinin tai sen biologisesti aktiivisten fragmenttien polypeptidianalogin tai sitä sisältävän hybridifuusioproteiinin valmistamiseksi sekä menetelmissä käyttökelpoisia DNA-sekvenssejä, vektoreita ja isäntäsoluja FI112367B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/013,801 US5420019A (en) 1993-02-02 1993-02-02 Stable bactericidal/permeability-increasing protein muteins
US1380193 1993-02-02
US9401235 1994-02-02
PCT/US1994/001235 WO1994018323A1 (en) 1993-02-02 1994-02-02 Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same

Publications (3)

Publication Number Publication Date
FI953658A0 FI953658A0 (fi) 1995-08-01
FI953658L FI953658L (fi) 1995-09-07
FI112367B true FI112367B (fi) 2003-11-28

Family

ID=21761817

Family Applications (3)

Application Number Title Priority Date Filing Date
FI953658A FI112367B (fi) 1993-02-02 1995-08-01 Menetelmiä bakterisidisen/läpäisevyyttä parantavan proteiinin tai sen biologisesti aktiivisten fragmenttien polypeptidianalogin tai sitä sisältävän hybridifuusioproteiinin valmistamiseksi sekä menetelmissä käyttökelpoisia DNA-sekvenssejä, vektoreita ja isäntäsoluja
FI20031199A FI115633B (fi) 1993-02-02 2003-08-26 Stabiilia bakterisidista/läpäisevyyttä parantavaa proteiinifragmenttia koodittava DNA, vektori, isäntäsolu ja menetelmä näiden proteiinifragmenttien valmistamiseksi
FI20050243A FI20050243A7 (fi) 1993-02-02 2005-03-07 Stabiilia bakterisidista/läpäisevyyttä parantavaa proteiinifragmenttia koodittava DNA, vektori, isäntäsolu ja menetelmä näiden proteiinipigmenttien valmistamiseksi

Family Applications After (2)

Application Number Title Priority Date Filing Date
FI20031199A FI115633B (fi) 1993-02-02 2003-08-26 Stabiilia bakterisidista/läpäisevyyttä parantavaa proteiinifragmenttia koodittava DNA, vektori, isäntäsolu ja menetelmä näiden proteiinifragmenttien valmistamiseksi
FI20050243A FI20050243A7 (fi) 1993-02-02 2005-03-07 Stabiilia bakterisidista/läpäisevyyttä parantavaa proteiinifragmenttia koodittava DNA, vektori, isäntäsolu ja menetelmä näiden proteiinipigmenttien valmistamiseksi

Country Status (18)

Country Link
US (6) US5420019A (de)
EP (3) EP1013760B1 (de)
JP (4) JP4139867B2 (de)
KR (1) KR100361997B1 (de)
CN (1) CN1142996C (de)
AT (3) ATE196650T1 (de)
AU (1) AU693089B2 (de)
CA (1) CA2155004C (de)
DE (3) DE69434980T2 (de)
DK (2) DK1310558T3 (de)
ES (2) ES2150983T3 (de)
FI (3) FI112367B (de)
GR (1) GR3034492T3 (de)
NO (3) NO315705B1 (de)
NZ (1) NZ262284A (de)
PT (2) PT1310558E (de)
WO (1) WO1994018323A1 (de)
ZA (1) ZA94703B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US6265187B1 (en) * 1989-02-14 2001-07-24 Incyte Pharmaceuticals, Inc. Recombinant endotoxin-neutralizing proteins
US6811989B1 (en) * 1989-02-17 2004-11-02 Bayer Corporation Pancreatic islet cell antigens obtained by molecular cloning
US5840836A (en) * 1989-02-17 1998-11-24 Bayer Corporation Pancreatic islet cell antigens obtained by molecular cloning
US6274348B1 (en) 1992-05-19 2001-08-14 Xoma Corporation Methods for the preparation of positively charged proteins
AU4382193A (en) * 1992-05-19 1993-12-13 Xoma Corporation BPI-immunoglobulin fusion proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5627153A (en) * 1994-01-14 1997-05-06 Xoma Corporation Anti-fungal methods and materials
ATE202482T1 (de) * 1993-03-12 2001-07-15 Xoma Technology Ltd Therapeutische verwendungen von antibakteriellen/durchlässigkeitserhöhenden proteinprodukten
US6214789B1 (en) 1993-03-12 2001-04-10 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
US5731415A (en) * 1993-06-17 1998-03-24 Xoma Corporation Lipopolysaccharide binding protein derivatives
WO1995002414A1 (en) * 1993-07-14 1995-01-26 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
US5770561A (en) * 1993-07-14 1998-06-23 Xoma Corporation Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
US6759203B1 (en) 1993-09-22 2004-07-06 Xoma Corporation Method for quantifying BPI in body fluids
EP0759774B1 (de) * 1993-09-22 2002-06-12 XOMA Technology Ltd. Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum
CN1133634A (zh) * 1993-09-22 1996-10-16 爱克斯欧玛公司 定量体液中的bpi的方法
WO1995019180A1 (en) * 1994-01-14 1995-07-20 Xoma Corporation Anti-gram-positive bacterial methods and materials
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5786324A (en) * 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5830860A (en) * 1994-03-24 1998-11-03 Regents Of The University Of Minnesota Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5578568A (en) * 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
US6271203B1 (en) 1994-07-07 2001-08-07 Xoma Corporation Anti-protozoan methods and materials
US5646114A (en) 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
AU4230396A (en) * 1994-11-08 1996-05-31 Novagen, Inc. Method for in vitro protein synthesis
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
WO1997004008A1 (en) * 1995-07-20 1997-02-06 Xoma Corporation Anti-fungal peptides
US5686414A (en) * 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation
JP2000501386A (ja) * 1995-11-14 2000-02-08 ゾーマ コーポレイション 角膜損傷に関連する病態を処置するための、殺菌性／透過性増強（ｂｐｉ）タンパク質
US5856159A (en) * 1996-03-27 1999-01-05 Cytel Corporation Production of galactosyltransferase
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
PT914144E (pt) * 1996-05-10 2001-05-31 Univ Texas Utilizacoes terapeuticas de produtos de proteinas bip contra a meningococcemia humana
CA2255539C (en) * 1996-05-23 2005-09-27 Xoma Corporation Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma
JP2000511892A (ja) 1996-05-24 2000-09-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 可溶性ベーターシート形成性ペプチドの合成
US5888973A (en) 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6482796B2 (en) * 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
CN1062564C (zh) * 1996-12-20 2001-02-28 周红 猪血中提纯杀菌性/通透性增加蛋白的方法
JP2001509167A (ja) * 1997-01-24 2001-07-10 エイブイアイ バイオファーマ，インコーポレイテッド Ｈ．ｐｙｌｏｒｉ感染を処置するための方法および結合体
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
FR2767323B1 (fr) * 1997-08-12 2001-01-05 Synt Em Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US6156514A (en) * 1998-12-03 2000-12-05 Sunol Molecular Corporation Methods for making recombinant cells
US6242219B1 (en) 1999-03-18 2001-06-05 Xoma (Us) Llc Methods for recombinant peptide production
US7041644B2 (en) * 1999-04-01 2006-05-09 Xoma Technology Therapeutic uses of BPI protein products in BPI-deficient humans
US6153584A (en) * 1999-04-01 2000-11-28 Levy; Ofer Therapeutic uses of BPI protein products in BPI-deficient humans
US6759241B1 (en) 1999-10-04 2004-07-06 University Of Maryland Biotechnology Institute Adjuvant comprising a lipopolysaccharide antagonist
AU2002241589B2 (en) * 2000-12-01 2007-07-19 Xoma Technology Ltd. Modulation of pericyte proliferation using BPI protein products or BPI inhibitors
US20030049616A1 (en) * 2001-01-08 2003-03-13 Sydney Brenner Enzymatic synthesis of oligonucleotide tags
WO2002070667A2 (en) * 2001-03-05 2002-09-12 Transtech Pharma, Inc. High level insect expression of rage proteins
CA2476427A1 (en) 2002-02-20 2003-08-28 Regents Of The University Of Minnesota Partial peptide mimetics and methods
WO2003083066A2 (en) * 2002-03-27 2003-10-09 Immunex Corporation Methods for increasing polypeptide production
DK1492874T3 (da) 2002-03-29 2011-03-14 Xoma Technology Ltd Multigene vektorplasmider og fremgangsmåder til forøgelse af ekspressionen af rekombinante polypeptider
US7906722B2 (en) * 2005-04-19 2011-03-15 Palo Alto Research Center Incorporated Concentrating solar collector with solid optical element
EP1741440A1 (de) 2005-07-08 2007-01-10 Mellitus S.L. Verwendung von BPI-proteine zur Behandlung von stoffwechselbedingten Erkrankungen und Herzkreislaufstörungen
ES2695999T3 (es) 2007-10-12 2019-01-11 Hoffmann La Roche Expresión de proteínas a partir de múltiples ácidos nucleicos
JP6040223B2 (ja) 2011-04-05 2016-12-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 放射線緩和剤および放射線保護剤としてのｂｐｉおよびその同類物
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
RU2750721C2 (ru) 2017-03-10 2021-07-01 Ф. Хоффманн-Ля Рош Аг Способ получения мультиспецифических антител

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4816566A (en) * 1983-06-01 1989-03-28 Hoffmann-La Roche, Inc. Polypeptides having interferon activity
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
US4677063A (en) * 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
EP0652230B1 (de) * 1987-08-11 2005-12-14 New York University Biologisch-aktive Bakterizide/permeabilitätserhöhende Proteinbruchstücke
US5576292A (en) * 1987-08-11 1996-11-19 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5770694A (en) * 1990-08-13 1998-06-23 Incyte Pharmaceuticals, Inc. Genetically engineered BPI variant proteins
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
EP0563222B1 (de) * 1990-12-03 1998-02-25 New York University Biologisch aktive bakterizide/permeabilitätserhöhende proteinbruchstücke
AU2872792A (en) * 1991-09-26 1993-04-27 Incyte Pharmaceuticals, Inc. A new form of liposaccharide binding protein (lbp)
WO1993009621A1 (en) * 1991-10-31 1993-05-13 Kwang Sil Lee Electronic identification system having remote automatic response capability and automatic identification method thereof
AU669723B2 (en) * 1992-05-19 1996-06-20 Xoma Corporation Improved methods for the preparation of endotoxin-binding proteins
AU4382193A (en) * 1992-05-19 1993-12-13 Xoma Corporation BPI-immunoglobulin fusion proteins
JP3946246B2 (ja) * 1993-02-02 2007-07-18 ゾーマ・コーポレイション 殺菌性／浸透性増大タンパク質（Ｂａｃｔｅｒｉｃｉｄａｌ／Ｐｅｒｍｅａｂｉｌｉｔｙ Ｉｎｃｒｅａｓｉｎｇ ｐｒｏｔｅｉｎ：ＢＰＩ）及び界面活性剤を含有する医薬組成物
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
ES2123134T3 (es) * 1993-03-12 1999-01-01 Xoma Corp Peptidos biologicamente activos de dominios funcionales de la proteina bactericida aumentadora de la permeabilidad y usos de los mismos.
EP0690721B1 (de) * 1993-03-12 1998-05-13 Xoma Corporation Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
ATE202482T1 (de) * 1993-03-12 2001-07-15 Xoma Technology Ltd Therapeutische verwendungen von antibakteriellen/durchlässigkeitserhöhenden proteinprodukten
AU6942994A (en) * 1993-04-30 1994-11-21 Incyte Pharmaceuticals, Inc. Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof

Also Published As

Publication number Publication date
EP1013760B1 (de) 2003-01-08
JP2004024276A (ja) 2004-01-29
US6828418B2 (en) 2004-12-07
US20060009383A1 (en) 2006-01-12
JP2006321813A (ja) 2006-11-30
FI20031199A7 (fi) 2003-08-26
ES2288199T3 (es) 2008-01-01
EP1310558A3 (de) 2003-08-13
PT689592E (pt) 2001-03-30
NO20050998D0 (no) 2005-02-24
CA2155004A1 (en) 1994-08-18
NO20023224D0 (no) 2002-07-03
EP1013760A2 (de) 2000-06-28
DE69426019T2 (de) 2001-05-17
HK1014548A1 (en) 1999-09-30
EP1013760A3 (de) 2000-08-09
US5420019A (en) 1995-05-30
GR3034492T3 (en) 2000-12-29
PT1310558E (pt) 2007-09-07
JP2004254697A (ja) 2004-09-16
ES2150983T3 (es) 2000-12-16
AU693089B2 (en) 1998-06-25
EP0689592A1 (de) 1996-01-03
NO953033L (no) 1995-10-02
US5674834A (en) 1997-10-07
NZ262284A (en) 1997-11-24
US6433140B1 (en) 2002-08-13
AU6170294A (en) 1994-08-29
FI953658A0 (fi) 1995-08-01
EP0689592B1 (de) 2000-09-27
FI115633B (fi) 2005-06-15
ATE196650T1 (de) 2000-10-15
DE69434980D1 (de) 2007-07-12
EP1310558A2 (de) 2003-05-14
NO315705B1 (no) 2003-10-13
ZA94703B (en) 1994-09-05
DK0689592T3 (da) 2000-10-16
DE69426019D1 (de) 2000-11-02
CN1120352A (zh) 1996-04-10
JPH08506586A (ja) 1996-07-16
DE69431995T2 (de) 2003-11-13
NO319156B1 (no) 2005-06-27
US5827816A (en) 1998-10-27
EP1310558B1 (de) 2007-05-30
KR960700340A (ko) 1996-01-19
KR100361997B1 (ko) 2003-04-08
DK1310558T3 (da) 2007-10-08
ATE230797T1 (de) 2003-01-15
FI20050243L (fi) 2005-03-07
DE69431995D1 (de) 2003-02-13
ATE363535T1 (de) 2007-06-15
NO20023224L (no) 1995-10-02
FI953658L (fi) 1995-09-07
FI20050243A7 (fi) 2005-03-07
CA2155004C (en) 2010-03-30
DE69434980T2 (de) 2008-01-24
WO1994018323A1 (en) 1994-08-18
JP4139867B2 (ja) 2008-08-27
CN1142996C (zh) 2004-03-24
NO953033D0 (no) 1995-08-01
US20030109436A1 (en) 2003-06-12
NO20050998L (no) 1995-10-02

Similar Documents

Publication Publication Date Title
FI115633B (fi) Stabiilia bakterisidista/läpäisevyyttä parantavaa proteiinifragmenttia koodittava DNA, vektori, isäntäsolu ja menetelmä näiden proteiinifragmenttien valmistamiseksi
WO1993023434A2 (en) Bpi-immunoglobulin fusion proteins
US5703038A (en) Therapeutic uses of bactericidal-permeability-increasing protein dimer products
Mizutani et al. The long amino-terminal tail domain of annexin XI is necessary for its nuclear localization
AU691175B2 (en) Novel polypeptide, DNA coding for said polypeptide, recombinant vector containing said DNA, recombinant virus prepared using said vector, and use thereof
US5861307A (en) Human s-myc-like polypeptide and a gene coding for said polypeptide
US5700690A (en) Compositions and methods for inhibiting fibrogenesis
HK1014548B (en) Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same
HK1028787A (en) Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same
WO2000064933A1 (fr) Proteine inhibitrice d'activation transcriptionnelle
EP1673099A1 (de) Zusammensetzungen und verfahren zur hemmung der zellseneszenz und hyperproliferativer störungen
WO1998029544A9 (de)